JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
A toll-free helpline to be set up to help doctors and patients
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
